Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?


Drug Profile


Alternative Names: ACT-GRO-777; AGRO-100; AS1411

Latest Information Update: 26 Dec 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator University of Alabama; University of Louisville
  • Developer Advanced Cancer Therapeutics; James Graham Brown Cancer Center
  • Class Antineoplastics; Nucleotide aptamers; Oligodeoxyribonucleotides
  • Mechanism of Action Apoptosis stimulants; Nucleolin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pancreatic cancer; Acute myeloid leukaemia; Renal cell carcinoma
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Cancer
  • No development reported Neuroblastoma

Most Recent Events

  • 18 Dec 2018 Qualigen in-licenses novel cancer drug technology technology and exclusive rights to develop and commercialize ACT GRO 777 and related compounds from Advanced Cancer Therapeutics
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Neuroblastoma in USA (IV)
  • 03 May 2011 Preclinical trials in Neuroblastoma in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top